JPMorgan Seeks Clarity On Dyne Therapeutics' DYNE-101 Expansion, Regulatory Path
I'm PortAI, I can summarize articles.
JPMorgan analysts express concerns over Dyne Therapeutics' DYNE-101 strategy for DM1, citing regulatory uncertainty and investor apprehension regarding data updates. Analyst Tessa T Romero notes plans for a global Registrational Expansion Cohort in 2026 to support U.S. Accelerated Approval, but questions the lack of regulatory approval for the protocol. Investors seek clarity on regulatory sign-off, and Romero highlights the need for definitive progress to alleviate concerns. JPMorgan maintains a Neutral rating on DYN, lowering the price target from $18 to $17, with DYN stock down 1.6% at $12.06.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Benzinga The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments